Navigation Links
Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
Date:9/2/2009

SAN JOSE, Calif., Sept. 2 /PRNewswire/ -- Vascular Designs, a medical device company, today announced that its IsoFlow(TM) infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

(Photo:http://www.newscom.com/cgi-bin/prnh/20090902/SF69552)

The IsoFlow Infusion catheter enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy.*

"In select clinical situations, the benefits of delivering a local endovascular drug dose without systemic exposure can reduce complications, improve results, and benefit patients," said Dr. Michael Dake, former chief of interventional radiology and current professor of cardiothoracic surgery at Stanford University School of Medicine. "The IsoFlow catheter facilitates the use of regional infusion therapies, especially in cases of challenging arterial anatomy where it helps achieve these promises of targeted delivery. IsoFlow is a valuable addition to our treatment arsenal."

IsoFlow is a dual balloon catheter designed to isolate a specific treatment region within the body from blood flow. It allows the infusion of fluids into the region and the perfusion of blood past the region to keep the blood flow intact during treatment. One of the many unique features of the IsoFlow infusion catheter is the ability to deliver medications sideways while using pressure to push the medication into the targeted area. The IsoFlow catheter is inserted over a guide wire for precise positioning within a patient's body. Once in place, medication is infused and isolated when both of the catheter's balloons are simultaneously inflated using fluid via a single inflation lumen. To view an animation detailing this process, please visit www.vasculardesigns.com.

"We are thrilled to receive FDA 510(k) marketing clearance after working on the IsoFlow catheter for more than seven years," said Robert Goldman, CEO and founder of Vascular Designs. "But what is most important is that individuals battling life-threatening illnesses will have a breakthrough treatment option to pursue with highly targeted drug delivery."

"IsoFlow could have a huge impact on the way many of today's deadliest illnesses such as cancer are treated. This method of local delivery may cause tumors that were previously unresponsive to systemic chemotherapy to respond. Additionally, the IsoFlow catheter may be able to provide treatment for a number of other medical conditions for which local delivery would be an ideal option," continued Goldman. "The potential applications of IsoFlow are exciting. We are looking forward to seeing how physicians will leverage this breakthrough catheter medical device into practice and the impact that it will surely make on the prognosis of so many patients."

The IsoFlow infusion catheter is now available. For more information on Vascular Designs or to purchase IsoFlow, please visit www.vasculardesigns.com or call (408) 484-9010.

About Vascular Designs

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow(TM) infusion catheter. His personal experience of watching loved ones suffer from and succumb to cancer had a profound influence on the creation of IsoFlow.

Vascular Designs has received FDA 510(k) marketing clearance for IsoFlow, which enables the direct delivery of medications into targeted areas. An important application for the IsoFlow catheter may be in the treatment of cancer. IsoFlow enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With the IsoFlow catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

For more information on Vascular Designs or to purchase IsoFlow, please visit www.vasculardesigns.com or call (408) 484-9010.

* Chrysos, E., et al. Treatment of Unrescectable Malignant Abdominal, Pelvic and Thoracic Tumors Using Abdominal Pelvic and Thoracic Stop-flow Chemotherapy. Anticancer Research, Sept.-Oct. 2001. 21(5):3669-3675.

Collins, J.M., Pharmacologic Rationale for Regional Drug Delivery. Journal of Clinical Oncology, Vol. 2, 498-504. 1984.

Lygidakis, N.J., Sgourakis, G. and Aphinives, P. Upper Abdominal Stop-flow Perfusion as a Neo and Adjuvant Hypoxic Regional Chemotherapy for Resectable Gastric Carcinoma: A Prospective Randomized Clinical Trial. Hepatogastroenterology, May-Jun. 1999. 46(27): 2035-2038.

Miotto, D., et al. Hypoxic Antiblastic Stop-flow Perfusion: Clinical Outcome and Pharmacokinetic Findings. Journal of Chemotherapy, Nov. 16, 2004. Suppl. 5: 44-47.

Pilati, P., et al. Stop-flow Technique for Loco-regional Delivery of Antiblastic Agents: Literature Review and Personal Experience. European Journal of Surgical Oncology, Aug. 28, 2002. 544-553.

    Media Contact:
    The Hoffman Agency
    (408) 975-3002
    isoflow@hoffman.com

    Sales Contact:
    Vascular Designs
    (408) 484-9010
   http://www.vasculardesigns.com/V2/contact.html


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sundia Receives the Highest Growth Potential Award from Zhangjiang
2. Heat forms potentially harmful substance in high-fructose corn syrup
3. A potential therapeutic agent for hepatic fibrosis
4. Herb Shows Potential for Rheumatoid Arthritis
5. Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose
6. ARKRAY Statement Regarding U.S. Food and Drug Administrations Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology
7. Researchers identify potential new avenue to attack cancer
8. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
9. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. New class of compounds discovered for potential Alzheimers disease drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of a ... go out of their way to be romantic, and may exaggerate a strength or ... any online dating profile. , A recent study from Queendom.com , however, ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Every winter, ... , This winter the West Penn Burn Center, part of the Allegheny ... #1, to bring you the “Space Heaters Need Space” campaign. , ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
(Date:2/11/2016)... DUNKIRK, N.Y. , Feb. 11, 2016  Governor ... Athenex that will create 1,400 jobs throughout ... by a partnership with the SUNY Polytechnic Institute, includes ... the Conventus Building in Buffalo , ... square foot manufacturing facility in Dunkirk ...
Breaking Medicine Technology: